Stepan Crenguta, Surawicz Christina M
University of Washington, Seattle, USA.
Acta Gastroenterol Latinoam. 2007 Sep;37(3):183-91.
Clostridium difficile-associated diarrhea usually occurs as a complication of antibiotic treatment. Recent data shows an increase in incidence rate of CDAD and higher rates of morbidity, colectomy and death. The management of CDAD involves discontinuing the inciting antibiotic agent and treatment with metronidazole or vancomycin. The reduced response rates and higher recurrence rates with metronidazole treatment reported in recent studies raise the question of the effectiveness of metronidazole therapy. After each recurrence, the risks for further relapses grow even bigger (after two recurrences, the risk being greater than 50%) and the management of recurrent CDAD becomes a challenge. Even after a careful review of available data on various drugs and having the experience of managing many cases of CDAD, one might find difficult to present with a successful "recipe" for treating severe CDAD. Every case is different and different management plans can lead to full recovery. First episode are metronidazole. If there is no improvement in three days or white blood cell count is more than 12,000 or creatinine level is high, metronidazole should be discontinued and vancomycin should be started. The latest trend of CDAD with more severe cases and increasing morbidity and mortality may be an incentive for using vancomycin as first line in some ases for RCDAD. Adding S boulardii to vancomycin or metronidazole from the first or second relapse and using pulse/tapering vancomycin therapy have been beneficial in decreasing the relapse rate. For patients with RCDAD, vancomycin therapy followed by rifaximin for two weeks looks promising. New therapies with, nitazoxanide, tinidazole, tiacumicin, rifaximin and ramoplanin are being evaluated and future reports and trials will show their efficacy. Immune therapy is also a promising option treatment in evaluation, showing seroconversion and protective antibody levels in initial tests in healthy volunteer. Passive immunization is also considered but for all these new therapy options, further randomized studies are needed. Prevention is also very important in controlling this disease: first by limiting the use of broad spectrum antibiotics and secondly by controlling the environmental spreading through gloves, handwashing and disposable thermometers.
艰难梭菌相关性腹泻通常作为抗生素治疗的并发症出现。近期数据显示艰难梭菌相关性腹泻的发病率增加,且发病率、结肠切除术和死亡率更高。艰难梭菌相关性腹泻的管理包括停用引发抗生素,并使用甲硝唑或万古霉素进行治疗。近期研究报道甲硝唑治疗的缓解率降低和复发率升高,这引发了甲硝唑治疗有效性的问题。每次复发后,进一步复发的风险会变得更大(两次复发后,风险大于50%),而复发性艰难梭菌相关性腹泻的管理成为一项挑战。即使在仔细审查了关于各种药物的现有数据并拥有管理许多艰难梭菌相关性腹泻病例的经验之后,人们可能仍难以给出一个成功治疗严重艰难梭菌相关性腹泻的“秘诀”。每个病例都不同,不同的管理计划都可能导致完全康复。首次发作时使用甲硝唑。如果三天内没有改善,或者白细胞计数超过12000,或者肌酐水平升高,应停用甲硝唑并开始使用万古霉素。艰难梭菌相关性腹泻病情更严重、发病率和死亡率不断增加的最新趋势可能促使在某些复发性艰难梭菌相关性腹泻病例中将万古霉素作为一线用药。从首次或第二次复发开始,在万古霉素或甲硝唑中添加布拉酵母菌,并使用脉冲/逐渐减量的万古霉素治疗,已有助于降低复发率。对于复发性艰难梭菌相关性腹泻患者,先使用万古霉素治疗,然后使用利福昔明治疗两周,看起来很有前景。硝唑尼特、替硝唑、替考拉宁、利福昔明和雷莫拉宁等新疗法正在评估中,未来的报告和试验将显示它们的疗效。免疫疗法也是一种有前景的评估中的治疗选择,在健康志愿者的初步试验中显示出血清转化和保护性抗体水平。也考虑过被动免疫,但对于所有这些新的治疗选择,都需要进一步的随机研究。预防在控制这种疾病方面也非常重要:首先是限制广谱抗生素的使用,其次是通过手套、洗手和一次性体温计控制环境传播。